Novo Nordisk A/S (NVO) to Release Quarterly Earnings on Wednesday

Key Points

• Novo Nordisk A/S is set to release its Q3 2025 earnings on November 5th, with analysts expecting earnings of $0.90 per share and revenue of $11.9832 billion.
• The company's last reported earnings beat expectations with $0.97 EPS and a revenue of $11.69 billion, exhibiting a net margin of 35.60%.
• Novo Nordisk's stock has faced a 1.7% decline, and the company has a market capitalization of $232.15 billion with a current P/E ratio of 14.28.

Novo Nordisk A/S (NYSE:NVO - Get Free Report) is projected to issue its Q3 2025 results before the market opens on Wednesday, November 5th. Analysts expect the company to announce earnings of $0.90 per share and revenue of $11.9832 billion for the quarter. Parties can check the company's upcoming Q3 2025 earningsummary page for the latest details on the call scheduled for Wednesday, November 5, 2025 at 7:00 AM ET.

Novo Nordisk A/S (NYSE:NVO - Get Free Report) last issued its earnings results on Wednesday, August 6th. The company reported $0.97 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.93 by $0.04. The firm had revenue of $11.69 billion during the quarter, compared to analyst estimates of $77.51 billion. Novo Nordisk A/S had a net margin of 35.60% and a return on equity of 78.64%. On average, analysts expect Novo Nordisk A/S to post $4 EPS for the current fiscal year and $5 EPS for the next fiscal year.

Novo Nordisk A/S Stock Down 1.7%

Shares of NVO opened at $51.99 on Wednesday. The firm has a market capitalization of $232.15 billion, a P/E ratio of 14.28, a P/E/G ratio of 2.40 and a beta of 0.68. Novo Nordisk A/S has a 12-month low of $45.05 and a 12-month high of $113.76. The company has a current ratio of 0.78, a quick ratio of 0.56 and a debt-to-equity ratio of 0.52. The firm has a fifty day moving average price of $56.49 and a 200-day moving average price of $62.23.

Novo Nordisk A/S Cuts Dividend

The firm also recently disclosed a semi-annual dividend, which was paid on Tuesday, August 26th. Investors of record on Monday, August 18th were paid a $0.4119 dividend. The ex-dividend date of this dividend was Monday, August 18th. This represents a yield of 240.0%. Novo Nordisk A/S's dividend payout ratio is 22.53%.

Hedge Funds Weigh In On Novo Nordisk A/S

Hedge funds have recently modified their holdings of the stock. State of Wyoming increased its holdings in shares of Novo Nordisk A/S by 72.7% during the second quarter. State of Wyoming now owns 950 shares of the company's stock valued at $66,000 after acquiring an additional 400 shares in the last quarter. Binnacle Investments Inc increased its holdings in shares of Novo Nordisk A/S by 126.2% during the second quarter. Binnacle Investments Inc now owns 1,190 shares of the company's stock valued at $82,000 after acquiring an additional 664 shares in the last quarter. Revolve Wealth Partners LLC increased its holdings in shares of Novo Nordisk A/S by 8.7% during the fourth quarter. Revolve Wealth Partners LLC now owns 2,490 shares of the company's stock valued at $214,000 after acquiring an additional 200 shares in the last quarter. Gamco Investors INC. ET AL acquired a new position in shares of Novo Nordisk A/S during the second quarter valued at about $314,000. Finally, 44 Wealth Management LLC acquired a new position in shares of Novo Nordisk A/S during the second quarter valued at about $315,000. Institutional investors and hedge funds own 11.54% of the company's stock.

Analyst Upgrades and Downgrades

A number of research firms recently weighed in on NVO. BNP Paribas Exane raised shares of Novo Nordisk A/S from an "underperform" rating to a "neutral" rating and set a $54.00 price objective for the company in a research note on Wednesday, August 13th. Sanford C. Bernstein raised shares of Novo Nordisk A/S from a "market perform" rating to an "outperform" rating in a research note on Tuesday, September 9th. Weiss Ratings reaffirmed a "hold (c)" rating on shares of Novo Nordisk A/S in a research note on Tuesday, October 14th. HSBC set a $70.00 price objective on shares of Novo Nordisk A/S in a research note on Wednesday, October 1st. Finally, TD Cowen lowered their price objective on shares of Novo Nordisk A/S from $105.00 to $70.00 and set a "buy" rating for the company in a research note on Tuesday, August 19th. Two equities research analysts have rated the stock with a Strong Buy rating, seven have assigned a Buy rating, ten have issued a Hold rating and two have assigned a Sell rating to the stock. According to MarketBeat.com, Novo Nordisk A/S currently has a consensus rating of "Hold" and a consensus target price of $76.00.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.